Doctors are urging patients to follow an asthma action plan, take daily medications and keep a rescue inhaler available at home, school and work. Louisiana’s Well-Ahead Asthma Control Program also ...
Doctors identify pollution, indoor allergens, vaping and poor treatment adherence as primary drivers of rising respiratory ...
U.S. Asthma Therapeutics Market size to reach USD 17.46 Billion by 2035 and Europe to reach USD 14.11 Billion by 2035 as ...
AstraZeneca’s Trixeo Aerosphere receives European approval for maintenance treatment of asthma: Cambridge, UK Thursday, September 24, 2026, 09:00 Hrs [IST] AstraZeneca’s fixed ...
European Commission approves Trixeo Aerosphere, the first triple-combination inhaler for inadequately controlled asthma in patients 12+. Learn more now.
AstraZeneca announced on 23 September 2026 that the European Commission has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate, BGF 320/28.8/10μg) as a maintenance ...
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of ...
AstraZeneca PLC's fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF (320/28.8/10µg)) had been approved in the European Union (EU) as a ...
Trixeo is a fixed-dose triple-combination drug (budesonide/glycopyrronium/formoterol) used as maintenence treatment for patients aged 12 or older. The drug has formerly been approved in several ...
(Alliance News) - AstraZeneca PLC on Wednesday said the EU approved Trixeo Aerosphere for the maintenance treatment of asthma. The Cambridge, England-based pharmaceutical maker said the approval by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results